Top 10 Best Clinical and Contract Research Organisations in India in 2027
India has emerged as an important destination for clinical research, pharmaceutical development, biotechnology research and outsourced drug discovery. The country’s expanding pharmaceutical industry, growing biotechnology ecosystem, availability of qualified scientific professionals and established clinical research infrastructure have created opportunities for Contract Research Organisations (CROs) to support pharmaceutical companies, biotechnology firms, medical device manufacturers and healthcare organisations across the world. These organisations play an important role in developing new medicines, evaluating the safety and effectiveness of pharmaceutical products, conducting clinical trials and generating scientific evidence required for regulatory approvals.
Clinical and Contract Research Organisations provide specialised research services that allow pharmaceutical and biotechnology companies to outsource different stages of product development. Their responsibilities can include preclinical research, clinical trial planning, patient recruitment, clinical site management, bioavailability and bioequivalence studies, laboratory testing, pharmacovigilance, clinical data management, biostatistics and regulatory documentation. Some organisations specialise in early-stage drug discovery, while others provide comprehensive services covering clinical development from Phase I to Phase IV.
India has developed a diverse CRO ecosystem comprising domestic research companies and international clinical research organisations with substantial operations in the country. Organisations such as Syngene International, IQVIA, ICON, Veeda Lifesciences, Lambda Therapeutic Research and Cliantha Research provide different combinations of research, clinical development and pharmaceutical support services. Their capabilities serve both Indian and international pharmaceutical markets.
The following are the top 10 clinical and contract research organisations in India in 2027.
1. Syngene International Limited
Syngene International Limited is one of India’s prominent integrated contract research, development and manufacturing organisations, providing scientific research and development services to pharmaceutical, biotechnology and healthcare companies. Headquartered in Bengaluru, Karnataka, the company has established a substantial presence in the global life sciences industry through its integrated research infrastructure, scientific workforce and multidisciplinary capabilities. Its operations extend across drug discovery, development, clinical research, analytical services and manufacturing, allowing pharmaceutical companies to access several stages of the drug development process through a single research partner.
One of Syngene’s important strengths is its integrated research model. The organisation supports pharmaceutical companies from early-stage discovery through preclinical development, clinical development and manufacturing. Its drug discovery capabilities include medicinal chemistry, computational chemistry, biology, pharmacology and other scientific disciplines required to identify and evaluate potential drug candidates. These capabilities are particularly relevant for pharmaceutical companies seeking external scientific expertise to develop new therapeutic molecules without establishing extensive in-house research infrastructure.
Syngene also provides clinical development services covering early-stage and late-stage clinical research. Its capabilities include clinical trial management, bioanalytical testing, central laboratory services, pharmacokinetic analysis, clinical data management, biostatistics, regulatory support, pharmacovigilance and medical writing. Its human pharmacology infrastructure supports healthy-volunteer studies, bioavailability and bioequivalence research, drug interaction studies and Phase I clinical development. The company’s clinical research capabilities also extend to patient-based trials across different therapeutic areas.
Another important feature is its ability to connect discovery research with clinical development. Pharmaceutical companies frequently face challenges when transferring research programmes from laboratory development to human studies. Syngene’s integrated capabilities help address this requirement by providing access to multiple scientific services within its research ecosystem. This can support continuity in project management, documentation, analytical methods and research quality.
The organisation also has significant capabilities in biologics, small molecules, analytical development and manufacturing. Its facilities and scientific teams support global pharmaceutical companies that require specialised research services, process development and commercial manufacturing assistance.
Syngene’s combination of drug discovery, preclinical research, clinical development and manufacturing makes it a significant participant in India’s contract research industry. Its broad service portfolio is particularly relevant to pharmaceutical and biotechnology companies looking for an integrated research partner capable of supporting multiple stages of product development.
2. IQVIA India
IQVIA is a leading global healthcare intelligence, clinical research and technology services organisation with substantial operations in India. The company combines healthcare data, advanced analytics, technology platforms and scientific expertise to support pharmaceutical companies, biotechnology businesses, medical device manufacturers, healthcare providers and government organisations. Its Indian operations contribute to global clinical research programmes while also serving the requirements of India’s expanding pharmaceutical and healthcare industries.
A major component of IQVIA’s business is clinical research and development. The organisation provides clinical trial management, clinical operations, patient recruitment support, clinical data management, biostatistics, regulatory affairs, medical writing and pharmacovigilance. These services help pharmaceutical companies plan, manage and execute clinical studies across different geographical markets. Its global infrastructure is particularly valuable for sponsors conducting multinational clinical trials that require consistent research processes across several countries.
IQVIA’s clinical research capabilities cover different stages of drug development. Its teams support study feasibility, site selection, clinical trial planning, investigator engagement, regulatory submissions, patient enrolment, monitoring and data management. Clinical research programmes require coordination among investigators, hospitals, laboratories, regulatory authorities and sponsors. IQVIA provides operational and technological support to manage these activities throughout the study lifecycle.
The company’s healthcare data and analytics capabilities are another important differentiator. Clinical development increasingly depends on data-driven decision-making, including patient population identification, clinical trial feasibility, safety monitoring and real-world evidence generation. IQVIA uses healthcare information, technology platforms and analytical capabilities to support these requirements. Real-world data can also help pharmaceutical companies understand how medicines perform outside controlled clinical trial environments.
Pharmacovigilance is another significant service area. Pharmaceutical companies must continuously monitor the safety of medicines and report relevant adverse events to regulatory authorities. IQVIA supports drug safety operations, individual case processing, safety reporting, signal detection and related activities. Its technology-enabled services help manage large volumes of safety information generated during clinical development and after commercialisation.
IQVIA also provides services to the medical technology and consumer healthcare sectors. Its expertise in healthcare analytics, market intelligence and commercial operations enables it to support companies beyond conventional clinical research activities.
Its Indian workforce includes professionals from life sciences, healthcare analytics, information technology and consulting backgrounds. This combination allows IQVIA to provide clinical research services alongside technology and data management solutions. For pharmaceutical companies seeking a global clinical development partner with substantial Indian operations, IQVIA remains an important organisation in the country’s CRO landscape.
3. ICON plc
ICON plc is a global clinical research organisation with an established presence in India. The company works with pharmaceutical, biotechnology, medical device and healthcare organisations to support the development of new medicines and medical technologies. Its Indian operations contribute to international clinical research programmes and provide a broad range of clinical development services.
ICON’s services cover multiple stages of clinical development, including study planning, clinical operations, clinical trial management, regulatory affairs, clinical monitoring, data management and pharmacovigilance. Its Indian teams support more than 100 services across the clinical development and research value chain, making the country an important part of its global delivery network.
Clinical trial management is one of ICON’s major capabilities. Pharmaceutical companies conducting clinical studies need to coordinate research sites, investigators, patients, laboratories and regulatory documentation. ICON provides project management and operational support to ensure that clinical research activities are conducted according to approved protocols and applicable regulatory requirements. Its clinical monitoring teams help assess site compliance, review research documentation and support the protection of trial participants.
The organisation also provides feasibility assessment and clinical site identification services. Selecting appropriate hospitals and research institutions is important for successful clinical trials, particularly when studies involve specialised patient populations or complex therapeutic conditions. ICON supports sponsors in identifying suitable investigators and research locations based on study requirements.
Clinical data management and biostatistics form another important part of its service portfolio. Clinical trials generate substantial volumes of information relating to patient characteristics, treatment responses, laboratory findings and safety outcomes. These datasets must be collected, validated, analysed and documented appropriately. ICON provides services to support data quality, statistical analysis and clinical reporting.
Its pharmacovigilance and medical affairs capabilities support the evaluation and monitoring of medicine safety throughout clinical development. The company also provides medical writing, central laboratory services, quality assurance and regulatory support.
ICON’s Indian operations are particularly relevant for pharmaceutical companies conducting international clinical trials. The organisation can combine local research expertise with its international infrastructure, supporting multinational studies that require coordinated execution across several countries.
Its capabilities in clinical operations, regulatory services, data management, medical writing and safety monitoring make ICON an important clinical research partner in India. It is particularly suited to sponsors seeking extensive global trial management capabilities supported by Indian research and operational teams.
4. Veeda Lifesciences
Veeda Lifesciences is an India-based global Contract Research Organisation headquartered in Ahmedabad, Gujarat. The company provides clinical, preclinical and bioanalytical research services to pharmaceutical, biotechnology and healthcare organisations. It has developed capabilities across different stages of drug development, supporting both innovative and generic pharmaceutical products.
The organisation is particularly recognised for its early clinical development capabilities, including bioavailability and bioequivalence studies. These studies are important for pharmaceutical companies developing generic medicines because they help establish whether a proposed product demonstrates comparable bioavailability to an appropriate reference medicine. Veeda provides research infrastructure and scientific expertise to conduct these studies in accordance with applicable regulatory requirements.
Its clinical research services cover early and late-stage development, including Phase I, Phase II, Phase III and Phase IV clinical trials. These services support different research requirements, from initial human exposure studies to larger patient-based investigations. The organisation works with pharmaceutical sponsors to manage study planning, clinical execution, research documentation and associated analytical requirements.
Veeda also provides bioanalytical services, which are essential for measuring drug concentrations and evaluating pharmacokinetic characteristics. Accurate bioanalytical results are important for understanding how a medicine is absorbed, distributed, metabolised and eliminated by the human body. The company supports these activities through specialised laboratories, validated analytical methods and experienced scientific teams.
Another important component of its service portfolio is preclinical research. Preclinical investigations provide scientific information about a potential drug candidate before it advances into human studies. Such research can include laboratory-based testing, safety assessments and other development activities required to evaluate potential products.
Veeda’s broader capabilities also support biosimilar and biotechnology development. Biosimilar products require comprehensive scientific evaluation to establish similarity to an existing biological reference product. This involves analytical characterisation, pharmacokinetic assessment, immunogenicity evaluation and, where required, clinical studies.
The company’s international presence and regulatory experience are relevant to pharmaceutical businesses seeking research support for products intended for different markets. Its combination of early clinical development, bioanalytical research and preclinical capabilities makes it an important Indian CRO.
Veeda is particularly relevant for pharmaceutical companies requiring specialised BA/BE studies, Phase I research, clinical development support and scientific services for generic and biosimilar products.
5. Lambda Therapeutic Research
Lambda Therapeutic Research is an Ahmedabad-headquartered global Contract Research Organisation providing clinical research and drug development services to pharmaceutical, biotechnology and generic medicine companies. Established in 1999, the organisation has developed an international operating presence, with facilities and operations supporting research programmes across India, North America and Europe.
One of Lambda’s major strengths is early-phase clinical development. The company has extensive experience in pharmacokinetic and pharmacodynamic studies, bioavailability and bioequivalence research, first-in-human investigations and other early-stage clinical programmes. These studies are essential for understanding the behaviour of drug candidates in the human body and establishing important information before further clinical development.
Lambda’s services include Phase I to Phase IV clinical trials. Early-phase research includes single ascending dose and multiple ascending dose studies, drug-drug interaction studies, food-effect studies, pharmacokinetic investigations, biosimilar studies and proof-of-concept research. These studies require carefully designed protocols, appropriate participant selection, continuous medical supervision and accurate laboratory measurements.
The organisation also provides late-phase clinical development services. Phase II and Phase III trials are important for evaluating the effectiveness and safety of potential medicines in patient populations. Phase IV studies help generate additional information after a product receives marketing approval. Lambda supports these programmes through clinical operations, patient and site strategy, monitoring, data management, biostatistics and medical writing.
Its bioanalytical services are another important component of its business. Clinical research programmes require validated analytical methods to measure drug concentrations and evaluate biological responses. Lambda provides specialised analytical support to meet these requirements and maintain consistency in research data.
The company also offers pharmacovigilance and regulatory affairs services. Regulatory documentation is a crucial component of clinical development because pharmaceutical companies must submit appropriate information to regulatory authorities before initiating studies and seeking product approvals. Lambda supports regulatory submissions, clinical trial applications, protocol amendments and other related requirements.
Its international infrastructure enables the organisation to support pharmaceutical companies undertaking clinical research across different regulatory jurisdictions. The combination of early-phase expertise, late-stage clinical trials, bioanalytical services and regulatory support makes Lambda a significant participant in India’s CRO industry.
Lambda is particularly relevant for companies requiring specialised clinical pharmacology research, BA/BE studies and integrated clinical development services for pharmaceutical and biotechnology products.
6. Cliantha Research
Cliantha Research is a global Contract Research Organisation with its Indian operations based in Ahmedabad, Gujarat, alongside facilities and operations in other international markets. The organisation provides integrated clinical research services to pharmaceutical, biotechnology, biosimilar, consumer healthcare and medical device companies. Its service portfolio covers early-phase clinical development, late-phase trials, bioanalytical research, clinical laboratory services and specialised consumer research.
The company’s early-phase clinical research capabilities include bioavailability and bioequivalence studies and Phase I clinical trials. These services support pharmaceutical manufacturers developing generic medicines, new chemical entities and other pharmaceutical products. Cliantha provides clinical infrastructure, participant management, laboratory support and scientific expertise required for these investigations.
Its late-phase clinical development services include Phase II, Phase III and Phase IV patient-based clinical trials. Such studies require coordination among investigators, healthcare institutions, patients, research teams and regulatory authorities. Cliantha supports these activities through clinical operations, study management, monitoring, data management and biostatistics.
Bioanalytical research is another important part of its business. The organisation provides laboratory services for small and large molecules, supporting pharmacokinetic studies, immunogenicity assessments and other analytical requirements associated with clinical development. Its clinical reference laboratories provide testing services for early-phase and late-phase research programmes.
An important feature of Cliantha is its specialised expertise in dermatology and consumer clinical research. Through its international research network and legacy capabilities, the organisation supports the testing of cosmetics, personal care products, nutraceuticals, over-the-counter products and medical devices. These studies can evaluate product safety, effectiveness, skin compatibility and specific performance claims.
The company also provides allergy testing and environmental exposure chamber research. Such facilities can be used for controlled investigations involving environmental allergens and respiratory responses. These specialised services support pharmaceutical, healthcare and consumer product companies requiring scientifically structured testing.
Cliantha’s additional capabilities include biostatistics, clinical data management, medical writing, clinical site management and regulatory support. Its international network enables it to support research programmes requiring access to multiple markets and research locations.
The organisation’s combination of pharmaceutical clinical trials, BA/BE research, bioanalytical services, dermatology and consumer research makes it a diversified participant in India’s clinical research industry. It is particularly relevant for companies seeking both conventional clinical development services and specialised testing capabilities for healthcare and personal care products.
7. Vimta Labs Limited
Vimta Labs Limited is an Indian contract research and testing organisation headquartered in Hyderabad, Telangana. The company has developed a broad research portfolio covering clinical research, preclinical research, pharmaceutical testing, analytical services, food testing, environmental testing and specialised laboratory investigations. Its presence across multiple scientific disciplines makes it a significant service provider for pharmaceutical, biotechnology and life sciences companies.
Clinical research is an important part of Vimta’s pharmaceutical development business. The organisation provides bioavailability and bioequivalence studies, clinical trials, patient pharmacokinetic studies, clinical endpoint investigations and biosimilar research. Its experience in clinical research extends across several therapeutic categories and different pharmaceutical dosage forms.
The company’s BA/BE services support pharmaceutical manufacturers seeking scientific evidence for generic product development and regulatory submissions. These studies evaluate the comparative performance of test and reference products under defined research conditions. Vimta supports study design, protocol preparation, regulatory documentation, participant recruitment, clinical execution and bioanalytical testing.
Its clinical development capabilities also include Phase II, Phase III and Phase IV clinical trials. These studies require access to investigators, hospitals, patients, research laboratories and clinical operations teams. Vimta provides research support to pharmaceutical companies through clinical trial management, monitoring, data management and associated scientific services.
Bioanalytical research is another major strength. The organisation uses specialised analytical instruments and validated methods to measure drug concentrations in biological samples. These measurements are essential for pharmacokinetic analysis and bioequivalence assessment. Its laboratory infrastructure also supports complex analytical requirements involving different pharmaceutical formulations and biological products.
Vimta provides specialised services for biosimilar research, including pharmacokinetic, pharmacodynamic, efficacy and immunogenicity assessments. Its broader clinical research capabilities extend to nutraceuticals, consumer products and product claim studies. These services can help companies evaluate product performance and generate scientific evidence for safety and efficacy claims.
The organisation’s experience in complex BA/BE studies, including studies involving specialised populations, inhalation products, topical formulations and other dosage forms, is an important part of its research portfolio.
Vimta also provides clinical laboratory testing, biostatistics, medical writing and regulatory affairs services. Its wider analytical and preclinical infrastructure enables pharmaceutical companies to access additional scientific support beyond conventional clinical trials.
With more than three decades of experience in clinical research and a diversified laboratory network, Vimta Labs remains an important Indian organisation for pharmaceutical testing, bioequivalence studies and clinical development programmes.
8. Fortrea India
Fortrea is a global clinical research and development services organisation with operations in India. The company was established as an independent organisation following the separation of Labcorp’s clinical development business. It provides clinical trial management, clinical development, regulatory and other research services to pharmaceutical, biotechnology and medical device companies.
India forms an important part of Fortrea’s international operational network. The organisation has a presence in locations including Bengaluru, Mumbai and Pune, supporting different functions associated with clinical development and research delivery.
Fortrea’s clinical research services cover the planning, execution and management of clinical trials. These activities include clinical operations, study management, site monitoring, patient recruitment support, regulatory documentation and data management. Pharmaceutical companies use such services to manage complex research programmes involving multiple clinical sites and different patient populations.
Clinical trial management requires substantial coordination between sponsors, investigators, hospitals and research professionals. Fortrea supports these activities through project management, operational oversight and clinical monitoring. Its teams help ensure that studies follow approved protocols and applicable research standards.
The organisation also supports clinical development programmes across different therapeutic areas. Clinical trials may involve complex diseases, specialised patient groups and products requiring detailed safety and efficacy evaluation. Such programmes require careful study design, clinical expertise and reliable research infrastructure.
Data management and statistical analysis are also important elements of clinical research. Clinical trial datasets must be collected and reviewed systematically to support reliable conclusions. Fortrea provides research and operational services that contribute to the management and analysis of clinical information.
Its global presence allows the company to support sponsors conducting multinational clinical studies. International pharmaceutical companies often require consistent research processes across different countries, and a global CRO can help coordinate local teams, research sites and operational requirements.
Fortrea’s Indian operations also contribute to the wider clinical development services industry through specialised scientific, technical and operational professionals.
The organisation is particularly relevant for pharmaceutical and biotechnology businesses seeking international clinical trial management capabilities with operational support in India. Its global research network and established clinical development services make it an important participant in the country’s CRO ecosystem.
9. SIRO Clinpharm
SIRO Clinpharm is an Indian clinical research organisation with a history dating back to 1996. Headquartered in Mumbai, Maharashtra, the organisation has developed experience in clinical research, clinical development support, medical writing, data management and functional service provision for pharmaceutical, biotechnology and healthcare companies.
The organisation has worked on different types of clinical research programmes, including proof-of-concept studies, multinational clinical trials and complex research involving specialised patient populations. Its experience in clinical project management and clinical operations is an important part of its service portfolio.
Clinical operations services include project management, clinical monitoring, study start-up, site management and other activities associated with clinical trial execution. These functions are necessary to coordinate clinical research programmes and ensure that participating sites follow the study protocol and relevant regulatory requirements.
SIRO’s broader business structure includes specialised service verticals that address different requirements within clinical development. SIRO Clintech provides full-service CRO capabilities, including study design, site management, clinical data management, biostatistics, medical writing and clinical trial supplies management.
The organisation also has a dedicated medical writing business. Medical writing is an important component of pharmaceutical development because clinical studies generate extensive scientific and regulatory documentation. These documents can include clinical study reports, regulatory submissions, safety reports, scientific publications and other research materials.
Its functional service provider capabilities are another significant offering. Pharmaceutical companies sometimes require external professionals to support particular functions within their existing clinical development teams rather than outsourcing an entire research programme. SIRO provides flexible staffing and functional support for clinical operations, project management, monitoring, data management, biostatistics and information technology.
This model can help sponsors address temporary resource requirements, access specialised expertise and expand operational capacity without creating additional permanent internal teams for every project.
SIRO also provides support for clinical trial supplies and associated research activities. Clinical trial supply management is important because investigational medicines and related materials must be prepared, managed and distributed according to study requirements.
The organisation’s experience in clinical development, functional staffing, medical writing and research management makes it a relevant Indian service provider. It is particularly suited to pharmaceutical and biotechnology companies seeking specialised clinical research support, medical documentation and flexible workforce solutions.
10. Jubilant Biosys
Jubilant Biosys is an Indian contract research, development and manufacturing organisation that provides drug discovery, preclinical development, research chemistry and pharmaceutical development services to global pharmaceutical and biotechnology companies. It operates as part of the Jubilant Pharmova group and has established research facilities in India and an international presence.
Unlike organisations that concentrate primarily on human clinical trials, Jubilant Biosys has a strong focus on early-stage drug discovery and preclinical research. Its services support pharmaceutical companies seeking to identify potential drug candidates, evaluate their biological activity and advance promising compounds towards further development.
The organisation’s drug discovery capabilities cover target identification, target validation, hit identification, hit-to-lead development, lead optimisation and preclinical candidate selection. These activities are important during the initial stages of pharmaceutical research, when scientists evaluate different compounds to identify those with the potential to become effective medicines.
Its scientific expertise includes medicinal chemistry, computational chemistry, structural biology, synthetic chemistry, in-vitro pharmacology, in-vivo pharmacology and drug metabolism and pharmacokinetics. These disciplines work together to evaluate the biological properties and development potential of pharmaceutical compounds.
Jubilant Biosys has capabilities in therapeutic research areas such as oncology, central nervous system disorders, metabolic diseases, pain and inflammation. Its scientists support pharmaceutical and biotechnology companies through customised research programmes designed around specific drug discovery requirements.
The organisation also provides services for advanced therapeutic research and large-molecule discovery. Its capabilities include antibody discovery and development-related research, including antibody-drug conjugates and monoclonal antibody programmes. These research areas are becoming increasingly important as pharmaceutical companies expand their focus beyond conventional small-molecule medicines.
Another important component of Jubilant Biosys is its contract development and manufacturing capability. The company supports pharmaceutical development, process development, analytical chemistry and manufacturing activities. This allows research programmes to progress from discovery into more advanced development and production stages.
Its business models include fee-for-service arrangements, full-time-equivalent partnerships and integrated research programmes. These models provide flexibility to pharmaceutical companies depending on the size, duration and complexity of their research requirements.
Jubilant Biosys is particularly relevant for companies seeking outsourced drug discovery, medicinal chemistry, preclinical research and development services. Its integrated scientific infrastructure and research expertise make it an important organisation in India’s broader contract research and pharmaceutical development industry.
Conclusion
India’s clinical and contract research industry has developed into an important component of the global pharmaceutical and biotechnology ecosystem. The country’s scientific workforce, research infrastructure, pharmaceutical manufacturing capabilities and expanding clinical trial network have created opportunities for domestic and international CROs to provide specialised services to global healthcare companies.
The organisations operating in this sector offer different combinations of clinical development, drug discovery, bioanalytical testing, preclinical research, pharmacovigilance, regulatory affairs and pharmaceutical development services. While companies such as Syngene International and Jubilant Biosys provide integrated research and development capabilities, organisations such as Veeda Lifesciences, Lambda Therapeutic Research, Cliantha Research and Vimta Labs have substantial expertise in clinical research and specialised laboratory services. International organisations such as IQVIA, ICON and Fortrea contribute global clinical development infrastructure and multinational trial management capabilities.
The growing importance of biotechnology, biosimilars, complex generics, personalised medicine and advanced therapeutic products is expected to create additional demand for specialised research services. Clinical research organisations will continue to play an important role in helping pharmaceutical companies evaluate new treatments, generate reliable scientific evidence and meet regulatory requirements across different markets.
As the Indian pharmaceutical industry continues to expand its research and development activities, CROs with strong scientific capabilities, reliable clinical infrastructure, regulatory expertise and comprehensive research services are likely to remain important partners in the development of medicines and healthcare innovations.
